Brokerages Set Mersana Therapeutics Inc (NASDAQ:MRSN) PT at $9.50

Shares of Mersana Therapeutics Inc (NASDAQ:MRSN) have earned an average rating of “Buy” from the six analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $9.50.

MRSN has been the subject of a number of research reports. Zacks Investment Research raised shares of Mersana Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, October 23rd. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Mersana Therapeutics in a report on Thursday, November 7th. Finally, ValuEngine raised shares of Mersana Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. NEA Management Company LLC grew its holdings in Mersana Therapeutics by 0.6% during the 3rd quarter. NEA Management Company LLC now owns 11,963,649 shares of the company’s stock worth $18,903,000 after acquiring an additional 69,382 shares during the period. Walleye Trading Advisors LLC acquired a new stake in Mersana Therapeutics during the 2nd quarter worth $57,000. Walleye Trading LLC acquired a new stake in Mersana Therapeutics during the 2nd quarter worth $54,000. Susquehanna International Group LLP acquired a new stake in Mersana Therapeutics during the 2nd quarter worth $154,000. Finally, Boxer Capital LLC acquired a new stake in Mersana Therapeutics during the 2nd quarter worth $8,440,000. 83.50% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:MRSN traded up $0.10 during midday trading on Thursday, hitting $2.74. The company’s stock had a trading volume of 612,500 shares, compared to its average volume of 258,040. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.12 and a current ratio of 5.12. The stock has a market capitalization of $126.41 million, a price-to-earnings ratio of -0.98 and a beta of 1.51. The stock’s 50 day simple moving average is $1.77 and its 200 day simple moving average is $3.24. Mersana Therapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $7.65.

Mersana Therapeutics (NASDAQ:MRSN) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.02. The business had revenue of $0.84 million during the quarter, compared to analyst estimates of $0.50 million. Mersana Therapeutics had a negative net margin of 79.49% and a negative return on equity of 41.14%. As a group, analysts anticipate that Mersana Therapeutics will post -0.6 EPS for the current year.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.

See Also: Is the QQQ ETF safe?

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit